Landec Corporation provided consolidated revenue guidance for full year fiscal 2022. For full year fiscal 2022, the company expected consolidated revenues: range of $179 million to $185 million (+4% to +8%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.03 USD | -2.90% |
|
+2.86% | -18.74% |
Jul. 01 | Lifecore Biomedical Agrees to Add 4 Board Members Under 22NW Deal to Avoid Proxy Fight | MT |
Jul. 01 | Lifecore Biomedical Announces Cooperation Agreement with 22NW | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.74% | 155M | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- LFCR Stock
- News Lifecore Biomedical, Inc.
- Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022